Search

Koji Tamada

from Lutherville Timonium, MD
Age ~56
Get Report
Related to:
Mutsumi Tamada, 54
Connected to:
Hiroshi Tamada, 55Issei Tamada, 47Masaaki Tamada, 60Melissa Tamada, 52Mitsuru Tamada, 96Seijiro Tamada, 51April N Tamaddoni, 54Cyrus S Tamaddon, 80Ehsan Tamaddon, 79Irandokht M Tamaddon, 93

Koji Tamada Phones & Addresses

  • 1714 Kurtz Ave, Lutherville Timonium, MD 21093
  • Lutherville, MD
  • 15919 Yukon Ln, Derwood, MD 20855
  • 4 Garston Ct, Cockeysville, MD 21030 (410) 667-3933
  • 2045 43Rd St, Rochester, MN 55901 (507) 529-1365

Publications

Us Patents

Compositions And Methods For The Treatment Of Immunologic Disorders

View page
US Patent:
8440185, May 14, 2013
Filed:
Dec 26, 2007
Appl. No.:
11/964599
Inventors:
Lieping Chen - Sparks Glencoe MD, US
Koji Tamada - Lutherville MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
Compositions and methods for preventing, reducing or inhibiting immunologic disorders are provided. Suitable compositions include one or more LIGHT-HVEM antagonists. LIGHT-HVEM antagonists include compounds that inhibit, reduce, or block the biological activity or expression of LIGHT and/or HVEM. LIGHT-HVEM antagonists can reduce or inhibit the binding of LIGHT to HVEM, but do not significantly modulate the binding of LTβ to LTβR. Suitable compositions include antibodies and antibody fragments, decoy polypeptides, small molecule inhibitors and inhibitory nucleic acids. Methods for using LIGHT-HVEM antagonists to reduce or inhibit T cell activation and survival are also provided. Therapeutic uses for LIGHT-HVEM antagonists to prevent or treat immunologic diseases and disorders including graft rejection, graft-versus-host disease, inflammatory immune responses, and autoimmune disorders are provided.

Compositions And Methods For Treating Inflammation

View page
US Patent:
20090214519, Aug 27, 2009
Filed:
Oct 4, 2006
Appl. No.:
12/083119
Inventors:
Lieping Chen - Sparks Glencoe MD, US
Koji Tamada - Lutherville MD, US
Assignee:
The John Hopkins University - Baltimore MD
International Classification:
A61K 39/395
G01N 33/68
A01K 67/00
A61P 29/00
US Classification:
4241301, 436 86, 800 13
Abstract:
The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject.

Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal

View page
US Patent:
20100203047, Aug 12, 2010
Filed:
Oct 3, 2008
Appl. No.:
12/680819
Inventors:
Koji Tamada - Lutherville MD, US
Lieping Chen - Sparks Glencoe MD, US
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395
C07K 16/18
C07K 16/28
US Classification:
4241331, 5303871, 53038822, 5303891, 5303873, 5303879, 4241301, 4241431
Abstract:
The present invention relates to compositions comprising an agent which activates herpes virus entry mediator (HVEM). The present invention also relates to compositions comprising an agonist of HVEM. The present invention also relates to methods of stimulating erythropoiesis in a mammal, comprising administering to a mammal a composition comprising an agent which activates HVEM, or is an agonist of HVEM. The present invention also relates to methods for treating an anemic disorder, comprising administering to a mammal suffering therefrom an agent which activates HVEM.

Immunotherapy For Contact Dermatitis Using Co-Signal Regulation

View page
US Patent:
20110268741, Nov 3, 2011
Filed:
Jan 5, 2010
Appl. No.:
13/143033
Inventors:
Koji Tamada - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395
A61P 17/00
C07K 16/28
US Classification:
4241431, 5303881
Abstract:
Compounds, compositions and methods for immunotherapy in contact dermatitis. Compounds and compositions (e.g. monoclonal antibodies) that stimulate the LAIR-1 expression pathway in LAIR-1 expressing immune cells and are useful for preventing or treating contact dermatitis are provided.

Inhibition Of B7-H1/Cd80 Interaction And Uses Thereof

View page
US Patent:
20110280877, Nov 17, 2011
Filed:
May 10, 2011
Appl. No.:
13/068337
Inventors:
Koji Tamada - Lutherville MD, US
International Classification:
A61K 39/395
A61P 31/18
A61P 35/00
A61P 31/12
C07K 16/18
A61K 39/00
US Classification:
4241341, 5303881, 4241411, 4242771, 4241331
Abstract:
The present invention provides a composition comprising an agent which specifically blocks interaction between B7-H1 and CD80 but not interaction between B7-H1 and PD-1 and a vaccine, optionally in a pharmaceutically acceptable carrier. Further provided is a method of treating or inhibiting abnormal cell proliferation or a viral infection in a host comprising the step of administering an agent which specifically blocks interaction between B7-H1 and CD80 but does not block interaction between B7-H1 and PD-1 in combination with a vaccine against the cancer to a host in need thereof.

Compositions And Methods For Treating Inflammation

View page
US Patent:
20130011835, Jan 10, 2013
Filed:
Jun 27, 2012
Appl. No.:
13/534925
Inventors:
Lieping Chen - Sparks Glencoe MD, US
Koji Tamada - Lutherville MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
G01N 33/566
C12Q 1/68
US Classification:
435 611, 435 792
Abstract:
The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject.
Control profile
Koji Tamada from Lutherville Timonium, MD, age ~56 Get Report